We are live on ! Find out more
VRDN icon

Viridian Therapeutics
VRDN

22 hedge funds and large institutions have $36.6M invested in Viridian Therapeutics in 2020 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

338% more capital invested

Capital invested by funds: $8.36M → $36.6M (+$28.3M)

55.71% more ownership

Funds ownership: 1.27% → 56.98% (+56%)

25% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 4

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

15% less funds holding

Funds holding: 26 → 22 (-4)

27% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 15

Holders
22
Holders Change
-4
Holders Change %
-15.38%
% of All Funds
0.39%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
11
Increased
5
Reduced
4
Closed
15
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
LGM
Logos Global Management
California
+$8.29M
2
RCM
RA Capital Management
Massachusetts
+$6.81M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
+$6.42M
4
CAM
Cormorant Asset Management
Massachusetts
+$1.4M
5
SCM
Soleus Capital Management
Connecticut
+$1.22M

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$3.01M
2
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
-$284K
3
JP Morgan Chase
JP Morgan Chase
New York
-$255K
4
VF
Virtu Financial
New York
-$87K
5
BlackRock
BlackRock
New York
-$86.8K
Name Holding Trade Value Shares
Change 		Change in
Stake
LGM
1
Logos Global Management
California
$9.05M +$8.29M +550,000 New
RCM
2
RA Capital Management
Massachusetts
$7.43M +$6.81M +451,932 New
Point72 Asset Management
3
Point72 Asset Management
Connecticut
$7.01M +$6.42M +426,162 New
AVA
4
Atlas Venture Advisors
Massachusetts
$3.45M – – –
Vanguard Group
5
Vanguard Group
Pennsylvania
$2.63M +$824K +54,633 +52%
CAM
6
Cormorant Asset Management
Massachusetts
$1.53M +$1.4M +93,126 New
SCM
7
Soleus Capital Management
Connecticut
$1.33M +$1.22M +81,185 New
Renaissance Technologies
8
Renaissance Technologies
New York
$878K +$729K +48,361 +959%
FFM
9
Fairmount Funds Management
Pennsylvania
$554K +$529K +35,092 New
DCM
10
Driehaus Capital Management
Illinois
$548K +$502K +33,333 New
BlackRock
11
BlackRock
New York
$508K -$86.8K -5,758 -16%
SFM
12
Sphera Funds Management
Israel
$502K +$460K +30,497 New
Citadel Advisors
13
Citadel Advisors
Florida
$330K +$136K +9,032 +82%
VA
14
VR Adviser
New York
$321K +$294K +19,495 New
Geode Capital Management
15
Geode Capital Management
Massachusetts
$257K -$28.4K -1,883 -11%
BI
16
BVF Inc
California
$160K +$147K +9,747 New
BCV
17
Banque Cantonale Vaudoise
Switzerland
$55K – – –
UBS Group
18
UBS Group
Switzerland
$36K +$33.6K +2,229 +17,146%
TRCT
19
Tower Research Capital (TRC)
New York
$23K +$18.6K +1,234 +781%
Wells Fargo
20
Wells Fargo
California
$8K -$1.58K -105 -18%
Morgan Stanley
21
Morgan Stanley
New York
$2K -$15 -1 -0.8%
Osaic Holdings
22
Osaic Holdings
Arizona
$1K +$1.21K +80 New
Fidelity Investments
23
Fidelity Investments
Massachusetts
– -$3.01M -259,244 Closed
Qube Research & Technologies (QRT)
24
Qube Research & Technologies (QRT)
United Kingdom
– -$284K -24,447 Closed
JP Morgan Chase
25
JP Morgan Chase
New York
– -$255K -21,290 Closed
1
2

VRDN Hedge Fund Activity: Q4 2020 in Review

22 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Viridian Therapeutics (VRDN) for Q4 2020, worth a combined $36.6M — up 338% from $8.36M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of VRDN and 11 opened new positions — a net loss of 4 holders — while 4 trimmed existing stakes and 5 added.

The largest buyer was Logos Global Management, opening a new position worth an estimated $8.29M. The largest seller was Fidelity Investments, exiting entirely with an estimated $3.01M sold.

  • 22 institutional investors held Viridian Therapeutics (VRDN) as of Q4 2020, down from 26 in Q3 2020.
  • Funds reported $36.6M of Viridian Therapeutics stock for Q4 2020, up 338% quarter-over-quarter.
  • 11 funds opened new Viridian Therapeutics positions in Q4 2020 and 15 closed out, a net change of -4 holders.
  • The largest Viridian Therapeutics buyer in Q4 2020 was Logos Global Management, an estimated $8.29M added.
  • The largest Viridian Therapeutics seller in Q4 2020 was Fidelity Investments, an estimated $3.01M sold.

Based on aggregated 13F filings for Q4 2020.